Qiming Weekly | Top 10 News from Qiming Venture Partners Portfolio Vol.34, 2026.11.3
Celebrating milestone moments with Qiming Venture Partners portfolio companies
Editor's Note: In 2026, the Qiming Weekly gets a refresh. Updated every week, it features ten handpicked highlights from Qiming Venture Partners' portfolio companies — covering funding milestones, breakthroughs, and more. Every step entrepreneurs take in the tide of technology and innovation deserves to be recorded. Qiming Venture Partners will continue to accelerate and empower founders, and we invite you to follow along as we mark these milestone moments together.
Funding
01/
Enjosim Closes RMB 200 Million Series B Round
Recently, Enjosim, a Qiming Venture Partners portfolio company specializing in high-precision drug delivery devices, announced the completion of a RMB 200 million Series B financing round, with Qiming Venture Partners participating. Proceeds will primarily go toward expanding global-scale manufacturing and delivery capabilities, accelerating R&D and commercialization of next-generation self-administration devices, and advancing overseas product registration, market expansion, and global customer service infrastructure.
Enjosim's product portfolio covers drug delivery scenarios for biologics including GLP-1, insulin, and growth hormone, encompassing disposable prefilled injection pens, reusable injection pens, and auto-injector devices. The company has established a fully integrated vertical smart manufacturing system spanning product design, mold development, precision injection molding, and automated assembly. Current annual production capacity exceeds 150 million injection pens, with a new manufacturing base planned for 350 million units. The company has obtained ISO 13485 and MDSAP certifications, and its products have secured regulatory approvals including EU CE, Canada MDL, India CDSCO, and Brazil ANVISA. It currently supplies supporting services to dozens of major domestic and international biopharmaceutical companies.
02/
Noitom Robotics Completes Pre-A+++ Round
Recently, Noitom Robotics, a Qiming Venture Partners portfolio company, announced the completion of a Pre-A+++ financing round. Noitom Robotics delivers "data" as its core product, providing high-quality, scalable multimodal training data and related infrastructure capabilities to robot OEMs, embodied intelligence model teams, universities, and research institutions. Qiming Venture Partners previously led its Pre-A+ round.
Leveraging technical expertise accumulated in high-precision motion capture and human data collection, Noitom Robotics has built three data systems: MOV (multimodal large-space interaction), OM (full-modality dexterous manipulation), and ITW+ (multimodal wild-collection egocentric vision). Standardized data processing, annotation, and quality control ensure data integrity, while cross-embodiment mapping technology enables adaptation and reuse across different robot platforms. Going forward, the company will continue refining its full-modality data service system, expanding scenario and task coverage to provide high-quality data support for embodied intelligence model training and real-world deployment.
Major Partnerships
01/
Brise Pharma Announces Global Licensing Agreement with AbbVie
Recently, Brise Pharma, a Qiming Venture Partners portfolio company and clinical-stage biopharmaceutical firm, disclosed updates on its exclusive licensing agreement with AbbVie. Signed in 2024, the agreement assigns Brise Pharma responsibility for drug discovery while AbbVie leads global development and commercialization of two Brise Pharma preclinical migraine programs. The potential total transaction value — including development, commercialization, regulatory, and sales milestone payments — reaches up to USD 757 million, plus future product sales royalties. As of the announcement date, Brise Pharma has achieved multiple near-term milestones.
Founded in Shanghai in June 2021, Brise Pharma is dedicated to developing multimodal therapies that systematically improve pain management for patients with migraine, nociceptive pain, neuropathic pain, and nociplastic pain. Through its proprietary drug discovery platform, the company integrates small-molecule and large-molecule approaches to modulate complex pain pathways at the molecular level. Its lead asset, BR005, is a novel oral small-molecule drug originating from China, currently in a registrational clinical trial for acute treatment of migraine in adults. The company is also advancing multiple next-generation innovative candidates toward IND submission.
02/
Matwings Technology Enters Strategic Partnership with Revvity
Recently, Matwings Technology, a Qiming Venture Partners portfolio company applying AI to life sciences, announced a formal strategic partnership with Revvity. The collaboration will focus on AI for Science, centered on bidirectional empowerment of "algorithms + hardware intelligence." It combines Matwings' capabilities in AI large models, protein design, and biological computing with Revvity's expertise in laboratory automation, life science solutions, and local manufacturing resources at its Taicang R&D and production base. The partnership targets core scenarios including drug discovery, protein engineering, and biomanufacturing, exploring a Lab-in-the-Loop R&D model to build an integrated full-chain solution of "AI algorithms + high-end research hardware + experimental services."
Matwings Technology's self-developed MatwingsVenus® wet-dry closed-loop protein R&D platform integrates computational design with automated experimental validation. The platform's foundation model, VenusREM, has long ranked first on the Harvard Medical School ProteinGym benchmark and was selected as a "Treasure of the Pavilion" at WAIC 2026.
03/
Shengshu Technology Signs Strategic Partnership with Tencent Cloud
Recently, Shengshu Technology, a Qiming Venture Partners portfolio company, announced a formal strategic partnership with Tencent Cloud. The two sides will pursue deep collaboration across video generation large model technology, cloud infrastructure, industry solutions, and ecosystem expansion, jointly driving industrial adoption and scaled application of AI video technology. At the model service layer, Shengshu Technology's full Vidu video generation model suite has officially launched on Tencent Cloud's large model service platform TokenHub, open for access by global developers and enterprise customers. Currently available models include the Vidu Q4 Preview and Q3 Pro from the Q series, as well as the Vidu S2 real-time interaction and editing model.
At the technology layer, the two parties have achieved deep integration of the Vidu S2 real-time digital human model with Tencent Cloud's real-time audio and video (TRTC) service, jointly building a real-time interactive digital human solution applicable to general internet entertainment, online education, live e-commerce, and intelligent customer service scenarios. At the market and ecosystem layer, both sides will jointly expand industry customers and overseas markets, developing joint solutions for advertising and marketing, gaming, education, cultural tourism, and media. Overseas market cooperation has officially commenced, with market alignment for Japan currently underway.
04/
Biren Technology and Shanghai Artificial Intelligence Laboratory Co-Host AI Agent/Skills Competition
Recently, Biren Technology (06082.HK), a Qiming Venture Partners portfolio company providing general-purpose intelligent computing solutions, announced that the award ceremony for the 2026 SuanShu International Intelligent Science Exploration Challenge and FeiXiang Cup AI Agent/Skills Development Competition — co-hosted with the Shanghai Artificial Intelligence Laboratory — was held in Shanghai. Launched in July, the competition attracted nearly 10,000 registrants from over 800 universities and institutions. It featured six tracks: life sciences, physical sciences, earth sciences, quantum computing, operator models, and free exploration. More than 400 Skills were submitted, all of which have been published on the SuanShu·DuanYan scientific discovery platform for open access.
As co-host and compute provider, Biren Technology supplied computing power and software stack environments for the competition, enabling real research problems and developer code to run on domestic computing hardware — a concentrated test of the maturity and usability of domestic compute software stacks. Building on this competition, Biren Technology, the Shanghai Artificial Intelligence Laboratory, and Shanghai Instrumentation Electronics jointly launched a shared compute pool initiative: Biren Technology and Shanghai Instrumentation Electronics will collaboratively provide supercomputing and AI computing resources, using the SuanShu·DuanYan scientific discovery platform as a vehicle to bring together universities, research institutes, and industry players, connecting scientific exploration, teaching and training, competition problem-solving, and industrial validation.
Product Launches
01/
Insilico Medicine Launches inClinico Agent for Clinical Trial Analysis and Prediction
Recently, Insilico Medicine (03696.HK), a Qiming Venture Partners portfolio company and generative AI-driven clinical-stage biotech, announced the launch of inClinico Agent, enabling intelligent analysis, design, and optimization of clinical study protocols. The system implements an agent-based orchestration framework that converts natural language queries into structured, end-to-end analytical workflows. Drawing on a curated proprietary database of over 100,000 clinical trial records and two machine learning models for specific endpoints, it compresses complex clinical landscape analyses that previously took months into minutes. For specific clinical studies, the system generates a trial prediction index from 0–100, assessing the likelihood of achieving the primary endpoint.
In real-world validation against 939 clinical studies completed in 2025, inClinico Agent achieved a prediction accuracy of 0.734 and AUROC of 0.805, with Phase III trial accuracy reaching 0.780. In a prospective head-to-head evaluation against five leading frontier large language models with real-time web search enabled — all predictions locked before trial results were announced — the LLMs were broadly optimistic, predicting approximately 75%–82% of trials would succeed. In contrast, inClinico Agent predicted roughly half (50%) would succeed, closely aligning with historical success rates in the biopharmaceutical industry (53% in the test set). Related research has been published on medRxiv. inClinico Agent is now formally open to industry partners and biopharmaceutical enterprise clients.
02/
Infinigence AI Open-Sources Embodied Intelligence Infrastructure RPent v0.1
Recently, Infinigence AI, a Qiming Venture Partners portfolio company building AI-native infrastructure, announced the v0.1 release of RPent (Recursive Physical Agent), an embodied intelligence infrastructure open-sourced in collaboration with Tsinghua University and Zhengxing Innovation. RPent employs an open modular architecture with unified tool interfaces, constructing a complete loop covering task planning, physical execution, environmental feedback, and experience reuse. It supports task planning using Agent Harnesses such as Codex and Claude Code, and provides a Memory system, Flash Mode for rapid execution, interactive CLI, and Web Dashboard.
In public benchmark evaluations, RPent based on GPT-6 Astra achieved a 92.63% task success rate on LIBERO-PRO. Through Flash Mode reusing successful task workflows, it realized approximately 6.8× execution acceleration on LIBERO-PRO. In real-robot validation, RPent v0.1 has completed tasks including tableware organization, pouring, visual recognition, and sorting storage on dual-arm Franka and YAM physical platforms. RPent is now open-sourced with a public evaluation leaderboard, supporting developer integration of new robots, models, and tools.
Technology Strength
DeepWay Joins "Vehicle-Road-Cloud Integration" Collaborative Development and Testing Initiative
Recently, DeepWay, a Qiming Venture Partners portfolio company, announced that at the 2026 World Intelligent Connected Vehicles Conference, it joined 22 industry partners in launching the 2027 "Vehicle-Road-Cloud Integration" collaborative development and testing action plan. Participants will leverage the Beijing-Tianjin-Hebei smart expressway network, Beijing high-level autonomous driving demonstration zone, and Western (Chongqing) Science City intelligent connected vehicle demonstration zone to advance a tiered, scenario-based open testing system, expand the scale of jointly developed and tested vehicle models, and drive mass production of relevant models. DeepWay's intelligent new energy heavy truck, the DeepWay Star Path, is among the 21 models participating in mass production development and testing.
As the world's first company to achieve mass delivery of forward-designed intelligent new energy heavy trucks, DeepWay provides a production-ready, reusable hardware foundation for vehicle-road-cloud integration validation through its native vehicle architecture. For L4 platooning vehicle-road-cloud deployment, the company has completed scenario research, requirements design, roadside survey, and cloud-side integration based on the Bayannur, Inner Mongolia trunk logistics corridor, and has initiated development of cloud collaborative functions for various scenarios. DeepWay joined the "Vehicle-Road-Cloud Integration" Chinese and foreign OEM collaborative development and testing action in May 2026; this further participation in scaled scenario validation will provide practical samples for large-scale deployment of intelligent connected heavy trucks and cost reduction and efficiency gains in trunk logistics.
R&D Progress
MediLink Therapeutics Presents Phase III Registrational Data for YL201 in Nasopharyngeal Carcinoma at ESMO
Recently, MediLink Therapeutics, a Qiming Venture Partners portfolio company, announced that the Phase III registrational study TAISHAN-301 of its B7-H3-targeting antibody-drug conjugate Tam-Peli (YL201) versus chemotherapy in heavily pre-treated recurrent or metastatic nasopharyngeal carcinoma — following the May announcement that interim analysis met the ORR primary endpoint — presented detailed data at the ESMO congress as a late-breaking abstract oral presentation. The study randomized 431 patients previously treated with PD-(L)1 inhibitors and at least two lines of chemotherapy, with the pre-specified first 254 patients analyzed for ORR. Data showed confirmed objective response rate was significantly higher in the Tam-Peli arm versus chemotherapy (50.8% vs 25.8%; OR 2.9, P<0.0001), with disease control rates of 93.7% and 75.8%, respectively.
For safety, Grade ≥3 treatment-related adverse events occurred in 49.3% of the Tam-Peli arm versus 51.7% in the chemotherapy arm. No Grade ≥3 infusion-related reactions or interstitial lung disease — prespecified adverse events of special interest — were observed. Developed on MediLink Therapeutics' self-developed TMALIN® platform, Tam-Peli is the world's first B7-H3 ADC to achieve positive results in a Phase III randomized controlled study. Its marketing application has been formally accepted by the Center for Drug Evaluation of the National Medical Products Administration. In January, MediLink Therapeutics entered into an exclusive licensing agreement with Roche for this product.
Past Issues
Qiming Weekly | Ten Highlights from Qiming Venture Partners Portfolio Companies Vol. 33, 2026.10.28
Qiming Venture Partners was founded in 2006. The firm currently manages 11 USD funds and 7 RMB funds, with total committed capital reaching USD 9.5 billion. Since inception, Qiming Venture Partners has focused on investing in early and growth-stage outstanding companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential companies in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ:HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ:WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Biren Technology (06082.HK), Zhipu (02513.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), APT Medical (688617.SH), Sanyou Medical (688085.SH), AmoyDx (300685.SZ), Sinocelltech (688520.SH), Insilico Medicine (03696.HK), AusperBio, Yuanxin Technology, MediLink Therapeutics, Leads Biolabs, StepFun, and others.